HighTower Advisors
MIST icon

HighTower Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

HighTower Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8K Buy
20,000
+10,000
+100% +$16K ﹤0.01% 3759
2026
Q1 		$11.9K Buy
+10,000
New +$17.5K ﹤0.01% 3780
2023
Q3 		– Sell
-31,000
Closed -$88K – 3688
2023
Q2 		$88K Buy
31,000
+4,800
+18% +$18.1K ﹤0.01% 3094
2023
Q1 		$103K Buy
+26,200
New +$95.8K ﹤0.01% 2941

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

HighTower Advisors's MIST Position: Q2 2026 in Review

HighTower Advisors increased its Milestone Pharmaceuticals (MIST) stake by 100% in Q2 2026, buying an estimated $16K and bringing the position to 20,000 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3759.

HighTower Advisors first reported a position in MIST in Q1 2023 and has held it in 4 quarters since. The position peaked at $103K in Q1 2023. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • HighTower Advisors held 20,000 shares of Milestone Pharmaceuticals worth $26.8K as of Q2 2026.
  • HighTower Advisors bought 10,000 Milestone Pharmaceuticals shares in Q2 2026, an estimated $16K.
  • Milestone Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3759 holding.
  • HighTower Advisors first reported a position in Milestone Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
  • HighTower Advisors's Milestone Pharmaceuticals position peaked at $103K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.